Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.DJO Surgical and Lima Corporate form partnership
The strategic partnership will allow Lima Corporate to distribute select DJO Surgical products in several countries in Europe, while Lima Corporate will provide products for sale in the
The strategic partnership will allow Lima Corporate to distribute select DJO Surgical products in several countries in Europe, while Lima Corporate will provide products for sale in the
AstraZeneca has also submitted a supplemental new drug application (sNDA) for Nexium for the risk reduction of low dose aspirin-associated gastric and/or duodenal ulcers. Nexium already is approved
ZymoGenetics has received rights to potential milestones and royalties, in exchange for licensing Seattle Life Sciences (SLS) rights to develop the product candidates. In addition, ZymoGenetics is entitled
The company has recently completed a Phase III clinical trial in the US with its flagship IV Alpha-1 Antitrypsin (AAT) product indicated for treating AAT deficiency and is
The Calix spinal implant system is reportedly designed to function as a cervical intervertebral fixation device as well as a vertebral body replacement device in the thoracic and
The product incorporates Circ Pharma’s drug delivery technology enabling once daily dosing. Circ’s technology provides for minimized delivery to the body during sleeping hours, acceleration of drug absorption
Australian pharmaceutical company Pharmaxis has reported positive results of its recently completed international Phase III trial of Bronchitol in people with cystic fibrosis. The primary endpoint of the
The patent, issued in Australia, covers Thymosin Beta 4, its analogues, isoforms and other derivatives and expires in 2022. Currently, RegeneRx is developing three product candidates, RGN-137, RGN-259
Biovail Laboratories International (BLS) has acquired the US and Canadian rights to develop, manufacture and commercialize pimavanserin tartrate in a number of neurological and psychiatric conditions, including Parkinson’s
Under the agreement, the two companies will develop diagnostic products that incorporate Fujirebio Diagnostics’s cancer biomarkers for use on Becton, Dickinson and Company’s (BD) multiplex testing platform. The